{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:48:28Z","timestamp":1774288108973,"version":"3.50.1"},"reference-count":42,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":35,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["A&amp;D Transl Res &amp; Clin Interv"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>The evoke\/evoke+ trials are investigating semaglutide in a population with early Alzheimer's disease (AD). Specific analyses of semaglutide safety data in older adults are limited; therefore, in the current analysis, we aimed to evaluate safety considerations with semaglutide in adults \u2265 65\u00a0years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Adverse event (AE) data from three semaglutide phase 3a programs in participants \u2265 65 years with type 2 diabetes and\/or overweight\/obesity were pooled. Change in body weight was also assessed in a smaller subset of participants \u2265 65 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      The analysis included 3529 participants \u2265 65 years. Baseline mean age and body mass index in participants \u2265 65 years were 69.3 to 70.2 years and 29.7 to 35.4\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , respectively, compared to 47.8 to 58.5 years and 31.3 to 36.7\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      in the overall population. AEs with semaglutide occurred in 73.6% to 92.4% of participants \u2265 65 years versus 73.2% to 90.8% of the overall population. AEs with semaglutide leading to permanent discontinuation appeared to be more frequent in participants \u2265 65 years (9.3%\u201312.4%) versus the overall population (5.7%\u20138.7%). Gastrointestinal disorders were the most frequently reported AEs with semaglutide in participants \u2265 65 years (44.6%\u201373.8%) and in the overall population (39.1%\u201373.4%). Participants aged \u2265 65 years receiving semaglutide had an estimated weight loss of 3.8% at week 52 compared to 0.1% with placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>Age \u2265 65 years did not appear to affect the safety considerations of semaglutide. The ongoing evoke\/evoke+ trials will elucidate the balance of efficacy and safety in the treatment of early AD with semaglutide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>This was a post hoc analysis evaluating adverse event (AE) data of semaglutide in people \u2265 65 years.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The most common AE with semaglutide was gastrointestinal (GI).<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>GI event rates were similar in people \u2265 65 years and the overall study populations.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/trc2.70076","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T02:48:01Z","timestamp":1746586081000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged \u2265 65 years"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8139-3309","authenticated-orcid":false,"given":"Marwan","family":"Sabbagh","sequence":"first","affiliation":[{"name":"Department of Neurology Barrow Neurological Institute Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Boschini","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  Bagsv\u00e6rd Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Cohen","sequence":"additional","affiliation":[{"name":"Toronto Memory Program  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Fugger","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  Bagsv\u00e6rd Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University Hospital of Cologne  Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sune","family":"Dandanell","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  Bagsv\u00e6rd Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue D.","family":"Pedersen","sequence":"additional","affiliation":[{"name":"C\u2010endo Diabetes and Endocrinology Clinic  Calgary Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Rafael Sol\u00eds","family":"Tarazona","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  Bagsv\u00e6rd Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanita R.","family":"Aroda","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-180766"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.10.024"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23095202"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0103"},{"key":"e_1_2_9_6_1","unstructured":"U.S. Food and Drug Administration.Highlights of Prescribing Information Saxenda.https:\/\/www.novo-pi.com\/saxenda.pdf"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0259"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12268"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1533317519899546"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102689"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102726"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14313"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30173-3"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.17925\/EE.2023.19.1.16"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1033479"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-143090"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0529-11.2011"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.063862"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2016.00108"},{"key":"e_1_2_9_20_1","unstructured":"EdisonP FemminellaGD RitchieCW et\u00a0al.Evaluation of liraglutide in the treatment of Alzheimer's disease.In:Alzheimer's Association International Conference. 29 July2021. Virtual meeting."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0749"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0883"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101737"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01666-7"},{"key":"e_1_2_9_25_1","unstructured":"ScheltensP AtriA FeldmanHH et\u00a0al.Baseline characteristics from evoke and evoke+: two phase 3 randomized placebo controlled trials of oral semaglutide in patients with early Alzheimer's disease. In:16th Clinical Trials on Alzheimer's Disease (CTAD) Boston MA USA 24\u201027 October2023."},{"key":"e_1_2_9_26_1","unstructured":"U.S. Food and Drug Administration.Highlights of Prescribing Information. Rybelsus. Accessed April 10 2025.https:\/\/www.novo-pi.com\/rybelsus.pdf"},{"key":"e_1_2_9_27_1","unstructured":"European Medicines Agency.Summary of Product Characteristics. Rybelsus. Accessed April 10 2025.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rybelsus-epar-product-information_en.pdf"},{"key":"e_1_2_9_28_1","unstructured":"U.S. Food and Drug Administration.Highlights of Prescribing Information. Ozempic. Accessed April 10 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf"},{"key":"e_1_2_9_29_1","unstructured":"European Medicines Agency.Summary of Product Characteristics. Ozempic. Accessed April 10 2025.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ozempic-epar-product-information_en.pdf"},{"key":"e_1_2_9_30_1","unstructured":"U.S. Food and Drug Administration.Highlights of Prescribing Information. Wegovy. Accessed April 10 2025.https:\/\/www.novo-pi.com\/wegovy.pdf"},{"key":"e_1_2_9_31_1","unstructured":"European Medicines Agency.Summary of Product Characteristics. Wegovy. Accessed April 10 2025.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/wegovy-epar-product-information_en.pdf"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14990"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14863"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645617"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2021.2002616"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01127-3"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30194-9"},{"key":"e_1_2_9_38_1","unstructured":"ArodaVR BauerR DaviesAL et\u00a0al.Insights from PIONEER 6 suggest effective patient management strategies may support treatment persistence with oral semaglutide. In:American Diabetes Association (ADA). 25\u201029 June2021. Virtual meeting."},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098615615472"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17011"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.16919"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13353"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14710"}],"container-title":["Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/trc2.70076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T09:24:27Z","timestamp":1761470667000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/trc2.70076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/trc2.70076"],"URL":"https:\/\/doi.org\/10.1002\/trc2.70076","archive":["Portico"],"relation":{},"ISSN":["2352-8737","2352-8737"],"issn-type":[{"value":"2352-8737","type":"print"},{"value":"2352-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2025-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70076"}}